Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis

Mark G. Lebwohl; Jeffrey L. Sugarman; Linda Stein Gold; David M. Pariser; Tina Lin; Radhakrishnan Pillai; Gina Martin; Susan Harris; Robert Israel

doi:10.1016/j.jaad.2018.09.002

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis

Mark G. Lebwohl
, Jeffrey L. Sugarman
, Linda Stein Gold
, David M. Pariser
, Tina Lin
, Radhakrishnan Pillai
, Gina Martin
, Susan Harris
, Robert Israel

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Original language	English
Pages (from-to)	282-285
Number of pages	4
Journal	Journal of the American Academy of Dermatology
Volume	80
Issue number	1
DOIs	https://doi.org/10.1016/j.jaad.2018.09.002
State	Published - Jan 2019

Access to Document

10.1016/j.jaad.2018.09.002

Cite this

Lebwohl, M. G., Sugarman, J. L., Gold, L. S., Pariser, D. M., Lin, T., Pillai, R., Martin, G., Harris, S., & Israel, R. (2019). Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 80(1), 282-285. https://doi.org/10.1016/j.jaad.2018.09.002

@article{aee623bd6e9143a68a4b49c3f383486d,

title = "Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01\% and tazarotene 0.045\% lotion in moderate-to-severe plaque psoriasis",

author = "Lebwohl, \{Mark G.\} and Sugarman, \{Jeffrey L.\} and Gold, \{Linda Stein\} and Pariser, \{David M.\} and Tina Lin and Radhakrishnan Pillai and Gina Martin and Susan Harris and Robert Israel",

note = "Funding Information: The authors acknowledge Brian Bulley, MSc, of Konic Limited for medical writing support. Ortho Dermatologics, a division of Valeant Pharmaceuticals North America LLC funded Konic's activities pertaining to this manuscript.",

year = "2019",

month = jan,

doi = "10.1016/j.jaad.2018.09.002",

language = "English",

volume = "80",

pages = "282--285",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "1",

}

Lebwohl, MG, Sugarman, JL, Gold, LS, Pariser, DM, Lin, T, Pillai, R, Martin, G, Harris, S & Israel, R 2019, 'Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis', Journal of the American Academy of Dermatology, vol. 80, no. 1, pp. 282-285. https://doi.org/10.1016/j.jaad.2018.09.002

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. / Lebwohl, Mark G.; Sugarman, Jeffrey L.; Gold, Linda Stein et al.
In: Journal of the American Academy of Dermatology, Vol. 80, No. 1, 01.2019, p. 282-285.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis

AU - Lebwohl, Mark G.

AU - Sugarman, Jeffrey L.

AU - Gold, Linda Stein

AU - Pariser, David M.

AU - Lin, Tina

AU - Pillai, Radhakrishnan

AU - Martin, Gina

AU - Harris, Susan

AU - Israel, Robert

N1 - Funding Information: The authors acknowledge Brian Bulley, MSc, of Konic Limited for medical writing support. Ortho Dermatologics, a division of Valeant Pharmaceuticals North America LLC funded Konic's activities pertaining to this manuscript.

PY - 2019/1

Y1 - 2019/1

UR - https://www.scopus.com/pages/publications/85056583797

U2 - 10.1016/j.jaad.2018.09.002

DO - 10.1016/j.jaad.2018.09.002

M3 - Article

C2 - 30227193

AN - SCOPUS:85056583797

SN - 0190-9622

VL - 80

SP - 282

EP - 285

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -